Alfred from Sweden

Registered at the short selling broker Skilling, 4 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Eli Lilly & Co. (LLY) shares information

Eli Lilly & Co.

24h Change

-0.89 %


Live rate: Market closed

Stock data per Thursday 13 Aug, 2020

New York Stock Exchange
-1.35 (-0.89%)
US Market is closed

Live Stock price in graph for Eli Lilly & Co. (LLY)

  • Latest Volume

    2,077,861 (-14.52 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change

    + 14.50 %

Quick links

Broker recommendations for Eli Lilly & Co.

The Eli Lilly & Co. stock is rated at 1.466667 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 13 August, 2020 by a total of 15 brokers. This means that the consensus of the 15 different brokers is leaning toward to overweight (moderate buy).

0 (0%)
0 (0%)
7 (46.67%)
0 (0%)
8 (53.33%)

Price target by analysts

The 11 latest analyst estimates, per Sunday 2 August, 2020, show the following high, low and average price targets.
Target Average: 174.27 USD
Target High: 190 USD
Target Low: 148 USD


Latest news about Eli Lilly & Co.

Below you can find the most recent news posts about Eli Lilly & Co., primarily from US and UK based news sources.

Insulin Pens Market and COVID-19 Impact Assessment 2020-2030 Featuring Novo Nordisk, Eli Lilly & Co, Sanofi and Ypsomed –

Tuesday, 11 August 2020, 18:25:00
DUBLIN–(BUSINESS WIRE)–The “Insulin Pens (Diabetes Care Devices) – Global Market Analysis and Forecast Model (COVID-19 market impact)” report has been added to’s offering. The market model is built to visualize quantitative market trends within Diabetes Care Devices therapeutic area. This model discusses in detail the impact of COVID-19 on Insulin Pens market for the year 2020 and beyond. Each of the covered 39 country’s color-coded and fully-sourced market models are e
— Business Wire

Eli Lilly, Innovent Deliver Encouraging Lung Cancer Data For Sintilimab

Monday, 10 August 2020, 09:02:46
Eli Lilly (LLY) and Innovent Biologics have announced encouraging interim analysis data from ORIENT-11 at the virtual IASLC World Conference on Lung Cancer … The post Eli Lilly, Innovent Deliver Encouraging Lung Cancer Data For Sintilimab appeared first on Smarter Analyst .
— Smarter Analyst

Australia experiencing critical shortage of antidepressants, contraceptives and HRT

Friday, 7 August 2020, 22:00:49
Reasons for shortages are often unclear and substitutes, which are not subsidised by PBS, are prohibitively expensive Australia is experiencing a critical shortage of key drugs including antidepressants, contraceptives and hormone replacement therapies, a situation that experts say highlights systemic problems with medicine supply in the country. Most of the shortages appear unrelated to coronavirus disruptions, although in the case of the popular antidepressant Prozac, the manufacturer, Eli Lilly, cites “unexpected increase in demand” during the crisis. Other manufacturers refuse to detail reasons for the supply problems. Continue reading…
— The Guardian

Eli Lilly Antibody Treatment Can Be Nursing Home ‘Safety Net’, Says Coronavirus Research VP

Friday, 7 August 2020, 20:07:35
With coronavirus affecting the senior population particularly hard, pharmaceutical company, Eli Lilly, is developing an COVID-19 antibody treatment meant to protect aging senior, particularly those in assisted living facilities.
— Cheddar

The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev

Friday, 7 August 2020, 16:02:02
The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev
— Yahoo Finance